natgillin/translations-raw huggingface dataset:
danazol, visse ACE-hæmmere (f.eks. captopril og enalapril) og angiotensin II--receptorblokkere.
danazol, some angiotensin converting enzyme (ACE) inhibitors (for example captopril, enalapril), and angiotensin II receptor blockers.
danazol, visse ACE-hæmmere (f.eks. captopril og enalapril) og angiotensin II-receptorblokkere.
danazol, some angiotensin converting enzyme (ACE) inhibitors (for example captopril, enalapril), and angiotensin II receptor blockers.
Danmark
Česká republika
Danmark Danmark
Denmark Denmark
Danmark sanofi-aventis Denmark A/S Tlf.: +45 45 16 70 00
Danmark sanofi-aventis Denmark A/S Tlf: +45 45 16 70 00
Dannelse af antistoffer mod GnRF for at inducere en midlertidig immunologisk suppression af testikelfunktionen.
Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function.
Dannelse af autoantistof
Autoantibody formation
dannelse af blodpropper f.eks. i lungerne kortåndethed.
blood clot for example in the lung (thromboembolic events) shortness of breath.
dannelse af blodpropper, som kan blive ført væk med blodcirkulationen (tromboemboliske reaktioner), og som kan resultere i f.eks.:blodprop i hjertet (hjerteinfarkt) (hvis du f.eks. får pludselige brystsmerter eller er stakåndet), slagtilfælde (hvis du f.eks. får pludselige anfald af muskelsvaghed, mærker følelsesløshed og/eller manglende balance, nedsat opmærksomhed eller talebesvær), blodpropper i lungerne (f.eks. hvis du har brystsmerter, vejrtrækningsbesvær eller hoster blod op), blodprop i dybtliggende vene (dyb venetrombose) (f.eks. hvis du rødmen, føler varme, smerter, ømhed eller hæver på det ene eller begge ben), brystsmerter, gener i brystet, smerter, når du trækker vejret, på grund af transfusionsrelateret lungesygdom (TRALI)
formation of blood clots which may be carried off in the blood circulation (thromboembolic reactions) and which may result e.g. in myocardial infarction (e.g. when you have sudden chest pain or shortness of breath), stroke (e.g. when you have a sudden onset of muscle weakness, have loss of sensation and/or balance, decreased alertness or difficulty in speaking), blood clots in the arteries of the lungs (e.g. when you have chest pain, difficulty in breathing or are coughing up blood), deep vein thrombosis (e.g. when you have redness, feel warmth, pain, tenderness, or have a swelling of one or both legs), chest pain, chest discomfort, painful respiration due to transfusion related lung injury (TRALI)
dannelse af en blodprop i venen i penis
formation of a blood clot inside the penile vein
Dannelse af glutathionkonjugater kan ikke helt udelukkes.
The formation of small amounts of glutathione conjugates cannot be completely excluded.
Dannelse af inhibitorer (neutraliserende antistoffer) er en kendt komplikation af behandlingen, og det bevirker, at behandlingen ikke længere virker.
The formation of inhibitors (antibodies) is a known complication that can occur during treatment, which stops the treatment working properly.
Dannelse af inhibitorer (neutraliserende antistoffer) er en kendt komplikation af behandlingen, og det er tegn på, at behandlingen ikke længere virker.
The formation of inhibitors (antibodies) is a known complication that can occur during treatment which stops the treatment working properly.
Dannelse af inhibitorer (neutraliserende antistoffer) er en kendt komplikation af behandlingen, og det er tegn på, at behandlingen ikke længere virker.
The formation of inhibitors (antibodies) is a known complication that can occur during treatment, which stops the treatment working properly.
Dannelse af inhibitorer (neutraliserende antistoffer) er en kendt komplikation til behandlingen, og det bevirker, at behandlingen ikke længere virker.
The formation of inhibitors (neutralising antibodies) is a known complication that can occur during treatment, which stops the treatment working properly.
Dannelse af neutraliserende antistoffer (inhibitorer) mod faktor VIII er en kendt komplikation ved behandling af patienter med hæmofili A. Disse inhibitorer er sædvanligvis IgG-immunglobuliner rettede mod prokoagulationsaktiviteten hos faktor VIII, som måles i Bethesda-enheder (BE) pr. ml plasma ved hjælp af det modificerede assay.
The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the FVIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma, using the modified assay.
Dannelse af neutraliserende antistoffer (inhibitorer) mod FVIII er en kendt komplikation ved behandling af patienter med hæmofili A. Disse inhibitorer er sædvanligvis IgG-immunglobuliner rettede mod prokoagulationsaktiviteten hos FVIII, som måles i Bethesda-enheder (BE) pr. ml plasma ved hjælp af det modificerede assay.
The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the FVIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma, using the modified assay.
Dannelse af neutraliserende antistoffer (inhibitorer) til faktor VIII er en kendt komplikation ved behandlingen af personer med hæmofili A. Disse inhibitorer er normalt IgG-immunoglobuliner, der retter sig mod faktor VIII prokoagulant-aktiviteten, og som kvantificeres i Bethesda-enheder (BE) pr. ml plasma ved hjælp af Nijmegen-modifikationen af Bethesda-analysen.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BUs) per mL of plasma using the Nijmegen modification of the Bethesda assay.
Dannelse af nitrogendioxid (NO2)
Formation of NO2
dannelse af unormale passager mellem dele af tarmen (fistler)
abnormal passages forming between parts of the intestine (fistula)
Dannelse eller tilstedeværelse af en blodprop i en blodåre – vene eller arterie (trombose)
Formation or presence of a blood clot within a blood vessel – vein or artery (thrombosis)
Dannelsen af anti-blinatumomab-antistoffer kan påvirke blinatumomabs farmakokinetik.
Anti- blinatumomab antibody formation might affect pharmacokinetics of blinatumomab.
Dannelsen af faktor IX i kroppen kontrolleres af faktor IX genet.
The production of factor IX in the body is controlled by the factor IX gene.
Dannelsen af neutraliserende antistoffer (hæmmere) mod faktor VIII er en kendt komplikation til behandlingen af personer med hæmofili A. Disse hæmmere er sædvanligvis IgG-immunoglobuliner rettet mod faktor VIII’s prokoagulante aktivitet, som kvantificeres i Bethesda Enheder (BE) pr. ml plasma ved brug af den modificerede test.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay.
Dannelsen af neutraliserende antistoffer (inhibitorer) mod faktor VIII er en kendt komplikation i behandlingen af individer med hæmofili A. Disse inhibitorer er sædvanligvis IgG immunoglobuliner rettet mod faktor VIII’s prokoagulante aktivitet, som kvantificeres i Bethesda Enheder (BE) per ml plasma ved brug af den modificerede test.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay.
Dannelsen af neutraliserende antistoffer (inhibitorer) mod faktor VIII er en kendt komplikation i behandlingen af individer med hæmofili A. Disse inhibitorer er sædvanligvis IgG-immunglobuliner rettet mod faktor VIII’s prokoagulante aktivitet, som kvantificeres i Bethesda Enheder (BE) pr. ml plasma ved brug af den modificerede test.
The formation of neutralising antibodies (inhibitors) against factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay.
Dannelsen af neutraliserende antistoffer (inhibitorer) mod faktor VIII er en kendt komplikation i behandlingen af patienter med hæmofili A. Disse inhibitorer er sædvanligvis IgG-immunoglobuliner rettet mod faktor VIIIs prokoagulante aktivitet, som kvantificeres i modificerede Bethesda Enheder (BE) pr. ml plasma ved brug af den modificerede test.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay.
Dannelsen af neutraliserende antistoffer (inhibitorer), mod faktor VIII er en kendt komplikation i behandlingen af patienter med hæmofili A. Disse inhibitorer er sædvanligvis IgG-immunoglobuliner rettet mod faktor VIIIs prokoagulante aktivitet, som kvantificeres i modificerede Bethesda Enheder (BE) pr. ml plasma ved brug af den modificerede test.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay.
Dannelsen af nogle CYP450-enzymer undertrykkes dog af øgede niveauer af cytokiner i forbindelse med kronisk inflammation.
The formation of some CYP450 enzymes is, however, suppressed by increased levels of cytokines during chronic inflammation.
Dannelsen af nogle CYP450-enzymer undertrykkes ved øget niveau af cytokiner under kronisk inflammation.
The formation of some CYP450 enzymes is suppressed by increased levels of cytokines during chronic inflammation.
Dannelsen af sådanne antistoffer er en kendt komplikation i behandlingen af patienter med hæmofili A. du tidligere har dannet antistoffer mod faktor VIII i forbindelse med et andet lægemiddel.
The formation of such antibodies is a known complication in the treatment of patients with haemophilia A. you have previously developed factor VIII inhibitors to a different product.
Dannelsen af sådanne neutraliserende antistoffer er en kendt komplikation i behandlingen af patienter med hæmofili A. du tidligere har dannet antistoffer mod faktor VIII i forbindelse med et andet lægemiddel.
The formation of such antibodies is a known complication in the treatment of patients with haemophilia A. you have previously developed factor VIII inhibitors to a different product.
dantrolen (infusion ved alvorligt forhøjet kropstemperatur); medicin som bruges til at beskytte mod organafstødning efter transplantation (ciclosporin).
dantrolene (infusion for severe body temperature abnormalities); medicines used to protect against transplant rejection (ciclosporin).
Dantrolen (infusion) Hos dyr er der set letal ventrikelflimren og kardiovaskulært kollaps i forbindelse med hyperkaliæmi efter indgift af verapamil og dantrolen i.v.
Dantrolene (infusion) In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene.
Dapagliflozin 10 mg som tillæg til saxagliptin
Dapagliflozin 10 mg add to saxagliptin
Dapagliflozin er en meget potent (Ki: 0,55 nM), selektiv og reversibel hæmmer af natriumglucose co- transportør 2 (SGLT2).
Dapagliflozin is a highly potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2).
Dapagliflozin er en potent (Ki: 0,55 nM), selektiv og reversibel hæmmer af natriumglucose co- transportstof 2 (SGLT2).
Dapagliflozin is a highly potent (Ki: 0.55 nM), selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2).
Dapagliflozin er ikke undersøgt i kombination med glucagon-lignende peptid 1 (GLP-1)-analoger.
Dapagliflozin has not been studied in combination with glucagon-like peptide 1 (GLP-1) analogues.
Dapagliflozin Hypoglykæmi
Dapagliflozin Hypoglycaemia
Dapagliflozin hæmmer ikke andre glucosetransportstoffer, som er vigtige for transport af glucose til de perifere væv, og det er > 1400 gange mere selektivt for SGLT2 som for SGLT1, det vigtigste transportstof i tarmen, som er ansvarlig for glucoseabsorption.
Dapagliflozin does not inhibit other glucose transporters important for glucose transport into peripheral tissues and is > 1,400 times more selective for SGLT2 versus SGLT1, the major transporter in the gut responsible for glucose absorption.
Dapagliflozin kombineret med metformin blev vurderet i 6 hovedundersøgelser med 3 200 voksne med type 2-sukkersyge.
Dapagliflozin in combination with metformin was evaluated in 6 main studies involving 3,200 adults with type 2 diabetes.
Dapagliflozin Placebo
Dapagliflozin 10 mg
Dapagliflozin som tillægsbehandling enten med metformin alene, metformin i kombination med sitagliptin, sulfonylurinstof eller insulin (med eller uden yderligere oral glucosesænkende medicin, herunder metformin) resulterede i statistisk signifikant gennemsnitlig reduktion i HbA1c efter 24 uger sammenlignet med forsøgspersoner, der fik placebo (p < 0,0001; Tabel 3, 4 og 5).
Dapagliflozin as an add-on with either metformin alone, metformin in combination with sitagliptin, sulphonylurea, or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant mean reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p < 0.0001; Tables 3, 4 and 5).
dapagliflozin virker ved at blokere proteinet natrium-glukose-kotransporter 2 (SGLT2) i nyrerne.
dapagliflozin works by blocking a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
Dapagliflozins glukuretiske virkning observeres efter den første dosis, er kontinuerlig over et doseringsinterval på 24 timer og opretholdes under hele behandlingens varighed.
Dapagliflozin’s glucuretic effect is observed after the first dose, is continuous over the 24-hour dosing interval, and is sustained for the duration of treatment.
Dapagliflozins metabolisme foregår primært via glukuronidkonjugering medieret af UDP- glukuronyltransferase-1A9 (UGT1A9).
The metabolism of dapagliflozin is primarily via glucuronide conjugation mediated by UDP glucuronosyltransferase 1A9 (UGT1A9).
Dapson (N-acetyltransferase- substrat)
(N-acetyltransferase
dapson til forebyggelse af lungebetændelse og behandling af hudinfektioner
dapsone, to prevent pneumonia and treat skin infections
dapson til forebyggelse af lungebetændelse og behandling af hudinfektioner.
dapsone, to prevent pneumonia and treat skin infections
dapson, til forebyggelse af lungebetændelse og til behandling af hudinfektioner
dapsone, to prevent pneumonia and treat skin infections
Daptomycin elimineres primært ved renal filtration, og derfor kan plasmaniveauer være forhøjede ved samtidig administration af lægemidler, som reducerer renal filtration (f.eks.
Daptomycin is primarily cleared by renal filtration and so plasma levels may be increased during co- administration with medicinal products that reduce renal filtration (e.g.
Daptomycin elimineres primært via nyrerne.
Daptomycin is eliminated primarily by the kidney.
Daptomycin er et naturligt cyklisk lipopeptid, som kun er aktiv imod grampositive bakterier.
Daptomycin is a cyclic lipopeptide natural product that is active against Gram positive bacteria only.
Daptomycin kan administreres intravenøst som infusion over 30 eller 60 minutter eller som injektion over 2 minutter.
Daptomycin may be administered intravenously as an infusion over 30 or 60 minutes or as an injection over 2 minutes.
Daptomycin viste ingen mutagen eller clastogen effekt i en række in vivo og in vitro genotoksicitetstests.
Daptomycin was not mutagenic or clastogenic in a battery of in vivo and in vitro genotoxicity tests.
Daptomycins farmakokinetik efter en enkelt 4 mg/kg dosis hos unge på 12-17 år er generelt tilsvarende farmakokinetikken hos raske voksne individer med normal nyrefunktion, med tendens mod lavere AUC og Cmax hos de unge.
The pharmacokinetics of daptomycin following a single 4 mg/kg dose in adolescents aged 12-17 years are generally similar to those of healthy adult subjects with normal renal function with trends towards lower AUC and Cmax in adolescents.
Daptomycins farmakokinetik efter en enkelt dosis Cubicin på 4 mg/kg blev evalueret i tre grupper pædiatriske patienter med vist eller mistænkt grampositiv infektion (2-6 år, 7-11 år og 12-17 år).
The pharmacokinetics of daptomycin after a single 4 mg/kg dose of Cubicin were evaluated in three groups of paediatric patients with proven or suspected Gram-positive infection (2-6 years, 7-11 years and 12-17 years).
Daptomycins farmakokinetik er generelt lineær og uafhængig af tid ved doser på 4 til 12 mg/kg administreret én gang daglig som intravenøs infusion over 30 minutter i op til 14 dage i raske frivillige.
Daptomycin pharmacokinetics are generally linear and time-independent at doses of 4 to 12 mg/kg administered as a single daily dose by 30-minute intravenous infusion for up to 14 days in healthy volunteers.
Daptomycins farmakokinetik ser ud til at være lineær i det undersøgte doseringsområde.
The pharmacokinetics of daptomycin appears to be linear in the dose range studied.
Daptomycins farmakokinetik ændres ikke hos patienter med moderat nedsat leverfunktion (Child-Pugh nedsat leverfunktion klasse B) sammenlignet med sunde frivillige probander, matchede mht. køn, alder og vægt, efter administration af en enkeltdosis på 4 mg/kg.
The pharmacokinetics of daptomycin is not altered in subjects with moderate hepatic impairment (Child-Pugh B classification of hepatic impairment) compared with healthy volunteers matched for gender, age and weight following a single 4 mg/kg dose.
Daptomycins fordelingsvolumen ved steady state hos raske, voksne personer var ca.
The volume of distribution at steady state of daptomycin in healthy adult subjects was approximately
Daratumumab binder til CD38, der findes i lavt niveau på erytrocytter, hvilket kan medføre en positiv indirekte Coombs test.
Daratumumab binds to CD38 found at low levels on red blood cells (RBCs) and may result in a positive indirect Coombs test.
Daratumumab bundet til erytrocytter kan maskere påvisning af antistoffer mod ubetydelige (minor) antigener i patientens serum.
Daratumumab bound to Red Blood Cells (RBCs) may mask the detection of antibodies to minor antigens in the patient’s serum;
Daratumumab er et humant monoklonalt IgG kappa-antistof, som kan påvises med såvel SPE-analyser (serumproteinelektroforese) som IFE-analyser (immunfiksering), der anvendes til klinisk monitorering af endogent M-protein (se pkt.
Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both, the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein (see section 4.5).
Daratumumab er ikke blevet undersøgt hos patienter med moderat nedsat leverfunktion (TB > 1,5 x til 3 x ULN og vilkårlig ASAT) eller svært nedsat leverfunktion (TB > 1,5 x til 3 x ULN og vilkårlig ASAT).
Daratumumab has not been studied in patients with moderate (TB > 1.5 x to 3 x ULN and any AST) or severe (TB > 3 x ULN and any AST) hepatic impairment.
Daratumumab er ikke blevet undersøgt hos patienter med moderat til svært nedsat leverfunktion (TB > 1,5 x ULN og vilkårlig ASAT), og der kan derfor ikke gives nogen anbefaling for disse patientpopulationer (se pkt.
Daratumumab has not been studied in patients with moderate to severe hepatic impairment (TB > 1.5 x ULN and any AST), therefore no dose recommendations can be made in these patient populations (see section 5.2).
Daratumumab kan detekteres i SPE-analyser (serumproteinelektroforese) og IFE-analyser (immunfiksering), som anvendes til at monitorere monoklonale sygdomsimmunglobuliner (M- protein).
Daratumumab may be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for monitoring disease monoclonal immunoglobulins (M protein).
Daratumumabs farmakokinetiske egenskaber efter intravenøs administration blev evalueret hos patienter med recidiverende og refraktær myelomatose ved dosisniveauer fra 0,1 mg/kg til 24 mg/kg.
The pharmacokinetics (PK) of daratumumab following intravenous administration were evaluated in patients with relapsed and refractory multiple myeloma at dose levels from 0.1 mg/kg to 24 mg/kg.
Darbepoetin alfa er fremstillet ved hjælp af genteknologi i ovarieceller fra kinesiske hamstre (CHO- K1).
Darbepoetin alfa is produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1).
Darbepoetin alfa i Aranesp fremstilles ved hjælp af en metode kaldet "rekombinant DNA-teknologi": Det fremstilles af celler, der har fået indsat et gen (DNA), som gør dem i stand til at producere darbepoetin alfa.
The darbepoetin alfa in Aranesp is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which make the cells able to produce darbepoetin alfa.
Darbepoetin alfa, det aktive stof i Aranesp, virker fuldstændig som det naturlige erythropoietin, der produceres i kroppen for at stimulere dannelsen af røde blodceller, men dets struktur er en anelse anderledes.
Darbepoetin alfa, the active substance in Aranesp, acts exactly like the natural erythropoietin made by the body to stimulate red blood cell production, but it is very slightly different in its structure.
Darifenacin er en lipofil base, 98% er bundet til plasmaproteiner (primært alfa-1-syre-glycoprotein).
Darifenacin is a lipophilic base and is 98% bound to plasma proteins (primarily to alpha-1-acid- glycoprotein).
Darifenacin metaboliseres efter oral indgift hovedsagelig i leveren.
Darifenacin is extensively metabolised by the liver following oral administration.
Darifenacins metabolisme medieres primært af cytochrom P450 enzymer CYP2D6 og CYP3A4.
Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.
Daronrix bør ikke gives til patienter, der har haft en anafylaktisk reaktion (en svær overfølsomhedsre- aktion) over for nogle af vaccinens komponenter eller over for nogen af de sporstoffer, den indeholder, f.eks. æg, kyllingeprotein eller gentamicin sulfat (et antibiotikum).
Daronrix should not be given to patients who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any substances found at trace levels in the vaccine, such as eggs, chicken protein or gentamicin sulphate (an antibiotic).
Daronrix er en "modelvaccine".
Daronrix is a ‘mock-up’ vaccine.
Daronrix er en hvid, let mælkeagtig væske, der leveres som følger:
Daronrix is a white, slightly milky liquid and is presented as follows:
Daronrix er en vaccine, der kun må bruges, når udbrud af en pandemi officielt er erklæret af Verdens- sundhedsorganisationen (WHO) eller af Den Europæiske Union (EU).
Daronrix is a vaccine that can only be used once a flu ‘pandemic’ has been officially declared by the World Health Organization (WHO) or European Union (EU).
Daronrix må ikke gives på samme tid som andre vacciner.
Daronrix should not be given at the same time as other vaccines.
Daronrix, injektionsvæske, suspension
Daronrix, suspension for injection.
Daronrix, injektionsvæske, suspension, flerdosisbeholder
Daronrix, suspension for injection in multidose container
Daronrix, injektionsvæske, suspension, i fyldt injektionssprøjte
Daronrix, suspension for injection in pre-filled syringe
Daronrix’ udseende og pakningsstørrelse
What Daronrix looks like and contents of the pack